Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC
Authors:
- Kohsuke IsomotoKIKohsuke Isomoto
- Koji HarataniKHKoji Haratani
- Takahiro TsujikawaTTTakahiro Tsujikawa
- Shuta TomidaSTShuta Tomida
- Yusuke MakutaniYMYusuke Makutani
- Masayuki TakedaMTMasayuki Takeda
- Kimio YonesakaKYKimio Yonesaka
- Kaoru TanakaKTKaoru Tanaka
- Tsutomu IwasaTITsutomu Iwasa
- Kazuko SakaiKSKazuko Sakai
- Kazuto NishioKNKazuto Nishio
- Akihiko ItoAIAkihiko Ito
Open Access
- 10 March 2026
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (10)
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 axis have revolutionized metastatic non–small cell lung cancer (mNSCLC) treatment. However, disease progression remains a concern, and the role of the complex tumor microenvironment (TME) in treatment failure is not fully understood. METHODS: In this biomarker study involving 103 patients with mNSCLC, including 81 patients who received ICI treatment, we evaluated the association between heterogeneous immune cell subsets and ICI efficacy through single-cell spatial profiling of pretreatment tumor tissue, using a 29-marker multiplex IHC platform built for in-depth dissection of the TME. RESULTS: Among various types of intratumoral lymphocytes, including Th1, Treg, and NK cells, only CD8 + T cells (tumor-infiltrating lymphocytes [TILs]) were associated with ICI efficacy. Computational tissue segmentation underscored the importance of direct physical interactions between CD8 + TILs and cancer cells for ICI efficacy. TIL phenotyping identified CD39/CD103/Ki-67 positivity as a hallmark of exhausted yet functional tumor-reactive CD8 + TILs. Immunosuppressive tumor-associated macrophages (TAMs) and cancer-associated fibroblasts were independent unfavorable adversaries. High CD73 expression on cancer cells was suggested to confer tolerance to ICI in EGFR/ALK -oncogene + NSCLC, potentially through M2-TAM accumulation and aberrant angiogenesis. CONCLUSION: Our study delineates the clinical relevance of heterogeneous immune cell subsets in ICI-treated mNSCLC, aiding the development of targeted therapeutic strategies. FUNDING: Osaka Cancer Society, KANAE Foundation for the Promotion of Medical Science, SGH Foundation, and YOKOYAMA Foundation for Clinical Pharmacology.Keywords
Funding Information
- the Osaka Cancer Society (No number)
- YOKOYAMA Foundation for Clinical Pharmacology (No number)
- SGH Foundation (No number)
- Kanae Foundation for the Promotion of Medical Science (No number)
This publication has 76 references indexed in Scilit:
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Journal of Clinical Oncology, 2017
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisClinical Cancer Research, 2016
- Perforin and granzymes: function, dysfunction and human pathologyNature Reviews Immunology, 2015
- CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer PatientsThe Journal of Immunology, 2015
- Single-cell RNA-seq: advances and future challengesNucleic Acids Research, 2014
- Autophagy-dependent ATP release from dying cells via lysosomal exocytosisAutophagy, 2013
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Deciphering and Reversing Tumor Immune SuppressionImmunity, 2013
- ATP is released from autophagic vesicles to the extracellular space in a VAMP7-dependent mannerAutophagy, 2012
- A Novel Transcription Factor, T-bet, Directs Th1 Lineage CommitmentCell, 2000